BioTuesdays

Category - News

BioTime
Markets

Dawson James starts BioTime at buy; PT $6

Dawson James Securities initiated coverage of BioTime (NYSE American:BTX) with a “buy” rating and $6 price target. The stock closed at $1.16 on Feb. 6. “We view BioTime as a new company invigorated by a new management...

February 7, 2019
Marinus Pharma
Markets

SVB Leerink starts Marinus Pharma at OP; PT $10

SVB Leerink launched coverage of Marinus Pharmaceuticals (NASDAQ:MRNS) with an “outperform” rating and sum-of-the-parts price target of $10. The stock closed at $3.66 on Feb. 5. Analyst Marc Goodman writes that his...

February 6, 2019
Trevena
Markets

HCW ups Trevena PT to $1.25 from 75c

H.C. Wainwright raised its price target for Trevena (NASDAQ:TRVN) to $1.25 from 75 cents, saying that resolution on two clinical requests from the FDA paves a path for the company’s NDA resubmission for oliceridine, a...

February 5, 2019
BioSig Technologies Logo
Executive Moves

BioSig appoints John Kowalski as VP of sales

BioSig Technologies (NASDAQ:BSGM) named John Kowalski as VP of sales to lead the commercial launch of the PURE EP signal acquisition and processing system, which is designed to improve the diagnosis and treatment of...

February 5, 2019
Rexahn Pharmaceuticals
Markets

HCW cuts Rexahn Pharma PT to $10 from $17

H.C. Wainwright lowered its price target for Rexahn Pharmaceuticals (NYSE American:PNN) to $10 from $17 to reflect a higher number of shares outstanding after an equity issue in January. The stock closed at 63 cents on...

February 5, 2019